Hikal Launches Advanced cGMP Pilot Plant in Pune

PUNE, India — Hikal Limited has officially commissioned an upgraded current Good Manufacturing Practice (cGMP) compliant pilot plant at its Research & Technology campus in Pune. The investment expands the company’s pharmaceutical development, scale-up, and clinical-stage manufacturing infrastructure, bridging the critical operational gap between laboratory-scale research and commercial-scale active pharmaceutical ingredient (API) production.

The development arrives as global pharmaceutical innovators face increasing pressure to accelerate clinical development timelines while meeting stringent regulatory standards. By offering combined scale-up, process development, and clinical material supply from a single innovation node in Pune, Hikal aims to shorten technology transfer timelines and improve process robustness for its global Contract Development and Manufacturing Organization (CDMO) client base.

Infrastructure and Technical Capabilities Expanded

The newly integrated pilot plant facility features enhanced processing infrastructure capable of handling complex synthetic chemistries under strict regulatory compliance.

The facility incorporates a diverse range of reactor capacities from 20 to 2,000 litres, constructed from stainless steel and glass-lined materials to accommodate varied chemical profiles. Advanced separation technology, including Hastelloy Agitated Nutsche Filter Dryers (ANFD), has been deployed to maintain high product purity during isolation.

Operational capabilities at the site support complex processes such as:

• Cryogenic Reactions: Low-temperature chemical processing for sensitive intermediates.

• High-Pressure Hydrogenation: Controlled catalytic reaction environments.

• High-Temperature Processing & High-Vacuum Distillation: Advanced purification of complex molecules.

Official Statements and Corporate Strategy

The commissioning forms part of Hikal's strategic capital deployment aimed at strengthening its market presence in global life sciences contract services.

According to official company announcements, the centralized setup allows cross-functional teams of research scientists and chemical engineers to directly oversee process performance, ensuring consistent quality control for early-stage and clinical-phase batches.

"The commissioning of our cGMP pilot plant is an important step in strengthening Hikal's pharmaceutical development and scale-up platform," said Sameer Hiremath, Vice Chairman and Managing Director of Hikal Limited. "It enhances our ability to support customers as they transition from laboratory development to larger-scale clinical programmes, while staying firmly anchored in quality, safety, and compliance."

Company officials noted that the facility creates a direct pathway for international clients seeking preclinical and clinical trial materials generated under global regulatory guidelines.

Strategic Impact on the Pharmaceutical Industry

The expansion underlines India's growing prominence in the global CDMO and pharmaceutical outsourcing landscape. For global pharmaceutical innovators, the availability of scalable cGMP-compliant capacity reduces technical risk during technology transfers.

For Hikal—which partners with life sciences firms across active ingredients, advanced intermediates, and specialty chemicals—the investment diversifies revenue streams toward high-value, research-intensive clinical development services.

Key Facts at a Glance

• Location: Hikal Research & Technology (R&T) Campus in Pune, Maharashtra.

• Compliance: Full current Good Manufacturing Practice (cGMP) regulatory standards.

• Equipment Range: Stainless steel and glass-lined reactors spanning 20L to 2,000L.

• Primary Purpose: Accelerating process development, technology transfer, and clinical-stage API production.

• Target Market: Global innovator pharmaceutical companies requiring CDMO support.

Frequently Asked Questions

What is the primary function of Hikal's new pilot plant in Pune?

The facility is designed for process development, technology transfer, and clinical-stage manufacturing. It enables Hikal to scale drug manufacturing processes from laboratory quantities to larger batches required for regulated clinical trial stages.

What chemical manufacturing capabilities does the plant feature?

The cGMP pilot plant is equipped with reactors ranging from 20 to 2,000 litres, Hastelloy filtration systems, and equipment for specialised operations including cryogenic reactions, hydrogenation, high-temperature synthesis, and high-vacuum distillation.

Why is cGMP compliance important for pilot plants?

cGMP compliance ensures that materials produced during the pilot phase meet international safety, purity, and quality standards required by drug regulators worldwide for preclinical testing and human clinical trials.

Source: Hikal Limited Official Portal, Indian Pharmaceutical Association, Bombay Stock Exchange (BSE Corporate Disclosures)